The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases

Bone

Volumn 46, Issue 3, 2010, Pages 801-805

  Lester, Jim E ^a   Brown, Janet E ^b   Hannon, Rosemary A ^c   Ellis, Sue P ^a   Horsman, Janet M ^a   Purohit, Omprakash P ^a   Coleman, Robert E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Bisphosphonates; Bone; Metastasis; N telopeptide; POCD

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE; TUMOR MARKER;

ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; FEMALE; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MALE; MYELOMA; POINT OF CARE TESTING; PROSTATE CARCINOMA; ROOM TEMPERATURE; URINALYSIS; BONE TUMOR; BREAST TUMOR; COMPARATIVE STUDY; HOSPITAL INFORMATION SYSTEM; MIDDLE AGED; OSTEOLYSIS; PHYSIOLOGIC MONITORING; PROCEDURES; SECONDARY; URINE; UTILIZATION;

BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; COLLAGEN TYPE I; FEMALE; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PEPTIDES; POINT-OF-CARE SYSTEMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77649184118     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.11.016     Document Type: Article

References (16)

1. Pavvlakis N, Stockler M (2002). Cochrane Database Systematic Review, 2002 Rosen LS, Gordon D, Tchekmedyian S et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic acid Lung Cancer and Other Solid Tumors Group. J Clin Oncol 2003; 21: 3150-3157.
2. Ebeling PR Potential candiadtes for bone turnover markers - N-telopeptide cross-links of type I collagen (NTX). Bone Markers: biochemical and clinical perspectives 2001, 28-38. Martin Dunitz, London. R. Eastell, M. Baumann, N.R. Hoyle, L. Wieczorek (Eds.).
3. Costa L, Demers L, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastasis status. J. Clin. Oncol. 2002, 20:850-856.
4. Ali S, Demers L, Leitzel K, Harvey A, Clemens D, Engle L, et al. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann. Oncol. 2004, 15:455-459.
5. Brown JE, Thomson C, Ellis S, Gutcher SA, Purohit OP, Coleman RE Bone resorption predicts for skeletal complications in metastatic bone disease. Br. J. Cancer 2003, 89:2031-2037.
6. Lipton A, Demers L, Curley E, Chinchilli V, Gaydos L, Hortobagyi G, et al. Markers of bone resorption in patients treated with pamidronate. Eur. J. Cancer 1998, 34:2021-2026.
7. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumours. J. Natl. Cancer Inst. 2005, 97:59-69.
8. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, et al. Predictive value of bone resorption and formation markers in cancer patients with metastasis receiving the bisphosphonate zoledronic acid. J. Clin. Oncol. 2005, 23(22):4925-4935.
9. Lipton A, Cook RJ, Major P, Smith MR, Coleman RE Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007, 12:1035-1043.
10. Hirsh V, Major P, Lipton A, Cook RJ, Langer CJ, Smith MR, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J. Thorac. Oncol. 2008, 3:228-236.
11. Hannon R, Sacco-Gigson N, Mallinak N, Ethgen D, Eastell R Comparison of ELISA and direct response device to measure urinary type 1 collagen N-telopeptide (NTX) in postmenopausal women. Arth. Rheum. 1999, 42:S290.
12. Hanson DA, Weis MA, AM B Specific immunoassay for monitoring human bone resorption: quantitation of Type I collagen crosslinked N-telopeptides in urine. J. Bone Min. Res. 1992, 7:1251-1258.
13. Blatt JM, Allen MP, Baddam S, Chase CL, Dasu BN, Dickens DM, et al. miniturized, self contained, single use, disposable assay device for the quantitative determination of the bone resorption marker, NTx, in urine. Clin. Chem. 1998, 44:2051-2052.
14. Bland JM, Altman DG Statistical method for assessing agreement between two methods of clinical measurement. Lancet 1986, 327:307-310.
15. UK Clinical Research Network: Portfolio Database. Cost-effective use of BISphosphonates in metastatic bone disease-a comparison of bone MARKer directed zoledronic acid therapy to a standard schedule-the BISMARK trial. Available at http://pfsearch.ukcm.org/StudyDetail.aspx?TopicID=&StudyID=1737.
16. Fizazi K, Lipton A, Mariette X, Suarez T, Body JJ, Rahim Y, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J. Clin. Oncol. 2009, 27:1564-1571.